New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2014
07:35 EDTLLY, BMY, MRK, PRGOPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
News For PRGO;BMY;LLY;MRK From The Last 14 Days
Check below for free stories on PRGO;BMY;LLY;MRK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 20, 2014
08:02 EDTBMYBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
August 18, 2014
17:37 EDTLLYFDA grants tentative approval for Lilly, Boehringer Basaglar insulin
Subscribe for More Information
11:41 EDTLLYCubist rises after report sparks takeover interest speculation
Subscribe for More Information
07:57 EDTMRK, BMYCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 15, 2014
10:01 EDTPRGOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:22 EDTPRGOPerrigo upgraded at B. Riley
As previously reported, B. Riley upgraded Perrigo to Buy from Neutral. The firm upgraded shares following the better than expected Q4 report and guidance and said it expects a return to consistent financial performance.
06:04 EDTPRGOPerrigo upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
August 14, 2014
10:06 EDTPRGOPerrigo sees FY15 revenue growth 7%-11%
Perrigo in earnings call presentation slides guided its FY15 revenue growth to 7%-11% above FY14. The company sees adjusted operating margin around 29% with an effective tax rate around 16%. Perrigo expects operating cash flow greater than $1B.
09:11 EDTPRGOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Kohl's (KSS), up 2.5%... Plug Power (PLUG), up 10%... Perrigo (PRGO), up 4.5%. HIGHER: Aruba Networks (ARUN), up 3% after shares upgraded at Stifel... KaloBios (KBIO), up 7.9% after publication shows EphA3 as target for anticancer therapy... Supernus (SUPN), up 4.4% after receiving FDA fast track designation for SPN-810. DOWN AFTER EARNINGS: Noodles & Company (NDLS), down 22%... Vipshop (VIPS), down 5.8%. LOWER: ExOne (XONE), down 10.7%, Voxeljet (VJET), down 6.6%, after earnings reports. Peers in the 3D space are lower as well, with Stratasys (SSYS) down 1% and 3D Systems (DDD) down 0.2%... Enphase Energy (ENPH), down 2.6% after filing to sell common stock for holders... InterMune (ITMN), down 3% after downgraded at Goldman following yesterday's advance on Bloomberg report that the company received takeover bids from Sanofi (SNY), Roche (RHHBY).
07:55 EDTPRGOPerrigo reports Q4 Consumer Healthcare sales $606.9M
Subscribe for More Information
07:55 EDTPRGOPerrigo sees FY15 adjusted EPS $7.20-$7.50, consensus $7.53
Subscribe for More Information
07:54 EDTPRGOPerrigo reports Q4 adjusted gross margin 44.5%
Subscribe for More Information
07:53 EDTPRGOPerrigo reports Q4 adjusted EPS $1.74 consensus $1.55
Subscribe for More Information
August 13, 2014
18:02 EDTMRKMerck provides statement on role of PNEUMOVAX 23 in updated ACIP recommendations
Subscribe for More Information
16:52 EDTMRKMerck confirms FDA approval of BELSOMRA
Subscribe for More Information
15:30 EDTMRKFDA approves Belsomra sleep drug
The Food and Drug Administration approved Belsomra tablets for use as needed to treat difficulty in falling and staying asleep. Belsomra is an orexin receptor antagonist and is the first approved drug of this type. Belsomra will be dispensed with an FDA-approved patient Medication Guide that provides instructions for its use and important safety information. Belsomra is a controlled substance because it can be abused or lead to dependence. Belsomra is made by Merck, Sharpe & Dohme.
15:05 EDTPRGONotable companies reporting before tomorrow's open
Subscribe for More Information
August 11, 2014
11:58 EDTLLYMannKind rallies after inking licensing agreement with Sanofi
Subscribe for More Information
August 8, 2014
10:03 EDTBMYBristol-Myers Hodgkin lymphoma treatment granted orphan drug status
Subscribe for More Information
August 7, 2014
11:02 EDTBMYBristol-Myers enters development pact with Leica Biosystem
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use